Anti-C5 Aptamer Complement Inhibition for Ocular Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-exudative age-related macular degeneration (AMD) lack effective inhibitors of the complement system, which contributes to disease progression, and existing therapies have limitations in specificity, toxicity, and administration methods.
Innovation Solution
Development of pegylated or unpegylated aptamers that specifically bind to complement components, particularly C5, to inhibit complement activation and modulate its function, thereby treating, stabilizing, or preventing non-exudative AMD by administering them via ocular or peri-ocular routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for non-exudative AMD, then treatment is provided, but specificity and toxicity profiles are inadequate
Solution Approach 1:
The invention segments the complement system into specific target components (C5, C3, factor B) and develops aptamers that selectively bind to individual components. This segmentation allows precise inhibition of specific complement pathways without broadly suppressing the entire complement system, thereby improving specificity while reducing off-target toxicity effects.
Solution Approach 2:
The aptamers serve as intermediary molecules that mediate between the complement system and therapeutic intervention. These nucleic acid-based intermediaries bind to specific complement proteins with high affinity, modulating their activity in a controlled manner that reduces uncontrolled inflammation and tissue damage while maintaining protective immune functions.
2Reliability
If complement system inhibition is implemented, then disease progression is slowed, but lack of effective inhibitors limits treatment success
Solution Approach 1:
The invention replaces traditional protein-based complement inhibitors with nucleic acid-based aptamers. This substitution leverages the advantages of nucleic acids including easier synthesis, lower immunogenicity, and higher stability, thereby providing effective complement inhibition with improved pharmacological properties and broader therapeutic adaptability.
Solution Approach 2:
The invention changes the fundamental parameter of inhibitor chemistry from protein-based to nucleic acid-based. This parameter change enables improved stability profiles, reduced immunogenicity, and more controllable pharmacokinetics, making complement inhibition therapy more effective and adaptable for treating non-exudative AMD.
3Reliability
If aptamers are administered via ocular or peri-ocular routes, then targeted delivery to the retina is achieved, but administration complexity increases
Solution Approach 1:
The invention extracts the therapeutic aptamer from systemic circulation and delivers it directly to the ocular compartment through intravitreal or peri-ocular injection. This extraction approach concentrates the drug at the target site (retina) while minimizing systemic exposure, achieving highly targeted delivery that reduces off-target effects and improves local efficacy despite requiring specialized administration procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-complement aptamers effectively inhibit complement protein cleavage and reduce symptoms of non-exudative AMD, maintaining visual acuity and retinal vessel density, and preventing neovascularization-associated bleeding and fluid accumulation, offering a more targeted and stable therapeutic approach compared to existing treatments.
Implementation Method 1
an aptamer which specifically binds to a complement component
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.